ValiRx PLC EAJF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBP 0.01
- Day Range
- GBP 0.01–0.02
- 52-Week Range
- GBP 0.01–0.68
- Bid/Ask
- GBP 0.00 / GBP 0.00
- Market Cap
- GBP 1.92 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 132.87
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.valirx.com
Valuation
|
Metric
|
EAJF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 132.87 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EAJF
|
|---|---|
Quick Ratio | 2.32 |
Current Ratio | 2.64 |
Interest Coverage | −520.15 |
Quick Ratio
EAJF
Profitability
|
Metric
|
EAJF
|
|---|---|
Return on Assets (Normalized) | −56.19% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −58.20% |
Return on Assets
EAJF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mgghplg | Dcpxvc | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Brbqmtgc | Gmlzxym | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ynctncfcx | Ngcp | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Rjrknwq | Hbf | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Btcxjltrc | Gbk | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ndbzmtjlq | Fqqrsm | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ynmpwjhj | Gmhgfq | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Ppsrmrpy | Djrcm | $12.8 Bil | |||
| Incyte Corp
INCY
| Mctmhgb | Mbnmrb | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hvkwwkysx | Wghpxv | $12.2 Bil |